Owen Bethan E, Rogers Ian R, Hoffman Martin D, Stuempfle Kristin J, Lewis Douglas, Fogard Kevin, Verbalis Joseph G, Hew-Butler Tamara
Sir Charles Gairdner Hospital, Australia.
St John of God Murdoch Hospital and University of Notre Dame, Australia.
J Sci Med Sport. 2014 Sep;17(5):457-62. doi: 10.1016/j.jsams.2013.09.001. Epub 2013 Sep 18.
To determine more conclusively whether intravenous (IV) administration of 3% saline is more efficacious than oral administration in reversing below normal blood sodium concentrations in runners with biochemical hyponatremia.
Randomized controlled trial.
26 hyponatremic race finishers participating in the 161-km Western States Endurance Run were randomized to receive either an oral (n=11) or IV (n=15) 100mL bolus of 3% saline. Blood sodium concentration (Na(+)), plasma protein (to assess %plasma volume change), arginine vasopressin (AVP), blood urea nitrogen (BUN) and urine (Na(+)) were measured before and 60 min following the 3% saline intervention.
No significant differences were noted with respect to pre- to post-intervention blood [Na(+)] change between intervention groups, although blood [Na(+)] increased over time in both intervention groups (+2 mmol/L; p<0.0001). Subjects receiving the IV bolus had a greater mean (± SD) plasma volume increase (+8.6 ± 4.5% versus 1.4% ± 5.7%; p<0.01) without significant change in [AVP] (-0.2 ± 2.6 versus 0.0 ± 0.5 pg/mL; p=0.49). 69% of subjects completing the intervention trial were able to produce urine at race finish with a mean (± SD) pre-intervention urine [Na(+)] of 15.2 ± 8.5 mmol/L (range 0-35; NS between groups). [BUN] of the entire cohort pre-intervention was 30.7 ± 10.5mg/dL (range 13-50).
No group difference was noted in the primary outcome measure of change in blood [Na(+)] over 60 min of observation following a 100mL bolus of either oral or IV 3% saline. Administration of an oral hypertonic saline solution can be efficacious in reversing low blood sodium levels in runners with mild EAH.
更确切地确定静脉注射3%盐水在纠正生化性低钠血症跑步者低于正常血钠浓度方面是否比口服更有效。
随机对照试验。
26名参加161公里西部各州耐力赛的低钠血症完赛者被随机分为两组,一组口服(n = 11)100毫升3%盐水推注,另一组静脉注射(n = 15)100毫升3%盐水推注。在3%盐水干预前及干预后60分钟测量血钠浓度(Na⁺)、血浆蛋白(以评估血浆容量变化百分比)、精氨酸加压素(AVP)、血尿素氮(BUN)和尿钠(Na⁺)。
尽管两个干预组的血[Na⁺]均随时间增加(增加2 mmol/L;p < 0.0001),但干预组间干预前后血[Na⁺]变化的主要结局指标无显著差异。接受静脉推注的受试者血浆容量平均增加幅度更大(+8.6 ± 4.5% 对比 1.4% ± 5.7%;p < 0.01),而[AVP]无显著变化(-0.2 ± 2.6对比0.0 ± 0.5 pg/mL;p = 0.49)。完成干预试验的受试者中有69%在比赛结束时能够排尿,干预前尿[Na⁺]平均(± SD)为15.2 ± 8.5 mmol/L(范围0 - 35;两组间无显著差异)。整个队列干预前的[BUN]为30.� ± 10.5mg/dL(范围13 - 50)。
在口服或静脉注射100毫升3%盐水推注后60分钟的观察期内,血[Na⁺]变化的主要结局指标在两组间无差异。口服高渗盐溶液可有效纠正轻度运动性低血钠症跑步者的低血钠水平。